← Older posts

Since the SGLT-2 inhibitors have been launched there have been studies that have suggested potential concerns such as ketoacidosis and amputation and those that have demonstrated positive benefits on cardiovascular outcomes. This meta-analysis of the drugs may dispel the anxieties … Continue reading

1 January 2018 – DVLA laws changed for Group 1 (car and motorcycle) drivers who are on medication that carries a hypoglycaemic risk (sulphonylureas, meglitinides, insulin). Previously the law stated that if they had ≥2 episodes of severe hypoglycaemia in … Continue reading

Diabetes

According to this article on The Conversation website, most people are familiar with type 1 and type 2 diabetes. Recently, though, a new type of diabetes has been identified: type 3c diabetes. This shows the value of doing our Diabetes … Continue reading

The formulation for Lucozade Energy is changing. If you are advising patients on on hypo treatment using Lucozade, amounts will double from 75-100mls to 150-200mls. Please click on the link below for a poster that you can share with your … Continue reading

        As this recent “fat map” continues to be widely reported in the press, our Clinical Director Linda Goldie has pointed out that more information is needed to draw conclusions. The map shows the rate of prescriptions … Continue reading

Today, we enter happily into the secret world (as far as NICE is concerned) of SGLT2 inhibitors. These clever drugs increase glucose excretion by the kidney thereby reducing blood glucose levels. When manufacturers produce new drugs they have to show, … Continue reading

After a long wait and several delays, the NICE Guidelines for type 2 diabetes have finally been released. Quickly scanning through the new guidelines, our diabetes clinical team here at the PCTC commented that common sense seems to have prevailed, … Continue reading

While we wait for updated diabetes guidelines, this excellent article by J.P. O’Hare et al considers what is right and wrong with the revised guidelines issued in June this year. Our Clinical Director Linda Goldie considers it a very worthwhile … Continue reading

NICE, in its infinite, government-financed wisdom is in the process of updating its Guidelines on the management of Type 2 Diabetes. A consultation document has already ruffled some feathers among consultants who have felt driven to use “no,no” phrases such … Continue reading

It’s been a week for bad news in Healthcare.  As well as the bad news about asthma mortality, are other items highlighting the increasing ineffectiveness of existing antibiotics and the high rate of hospital admissions for people with diabetes.  The … Continue reading

← Older posts
Page 1 of 512345